Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348347 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL30010382 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL14418567 | 0.79 | MAPK1 (0.42) | ALDH1A1MEN1MAPTKMT2AKCNH2 | |
| SCHEMBL22292142 | 0.78 | SCN10A (0.39) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL31292303 | 0.78 | SCN10A (0.40) | ALDH1A1KCNH2SCN10A | |
| SCHEMBL7521505 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL30010643 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL28105147 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL27920310 | 0.77 | BACE1 (0.50) | MEN1KMT2ATSHRKIF11 | |
| SCHEMBL2627057 | 0.77 | PRKCZ (0.46) | ALDH1A1HPGDALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 531 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6783927-B2 | CONTAINING SURFACTANT | FUJI PHOTO FILM, CO., LTD. (JP) | 2004-08-31 | — | — | US | claimed |
| CN-110579936-B | Thermally developable photosensitive material and medical film using the same | 柯尼卡美能达株式会社 | 2023-10-27 | — | — | CN | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| CN-110579936-A | Heat-developable photosensitive material and medical film using the same | 柯尼卡美能达株式会社 | 2019-12-17 | — | — | CN | disclosed |
| US-20180170923-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2018-06-21 | — | — | US | disclosed |
| EP-1072948-B1 | Thermally processed image recording material | FUJIFILM CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-20170001995-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160184305-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-6165707-A | Photothermographic or thermographic image-forming material | FUJI PHOTO FILM CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6156491-A | Heat developable light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6150084-A | NUCLEATING AGENT AND DIPHOSPHORUS PENTOXIDE-DERIVED COMPOUND; ANTIFOGGING AGENT, CONTRAST | FUJI PHOTO FILM CO., LTD. (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-1045284-A1 | Heat developing method for heat developable image recording material | FUJI PHOTO FILM CO., LTD. (JP) | 2000-10-18 | — | — | EP | disclosed |
| EP-1041433-A1 | Heat-developable photosensitive material and method for forming image using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1041435-A1 | Heat-developable photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1041434-A1 | Heat-developable photosensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 2000-10-04 | — | — | EP | disclosed |
| US-6100022-A | COMPRISES A NONPHOTOSENSITIVE ORGANIC SILVER SALT, A PHOTOSENSITIVE SILVER HALIDE AND A POLYMERIC BINDER HAVING GLASS TRANSITION TEMPERATURE OF-30 TO 40 DEGREE C. ON A SUPPORT, AND IMAGE FORMING LAYER CONTAINING NUCLEATING AGENT | FUJI PHOTO FILM CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| EP-0990946-A1 | Heat-developable photosensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| EP-0962812-A1 | Aqueous dispersion of fatty acid silver salt particles, method for redispersing fatty acid silver salt particles, photothermographic light-sensitive material, and method for producing the same | FUJI PHOTO FILM CO., LTD. (JP) | 1999-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170923-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | FOXM1, SF3B1, SF3B5 | ALDH1A1 336/4885HPGD 2399/4885ALOX15 1226/4885 |
| US-20160184305-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, SCN5A, SF3B5 | ALDH1A1 714/4885HPGD 1634/4885ALOX15 2323/4885 |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, PMP22 | ALDH1A1 741/4885HPGD 1812/4885ALOX15 2751/4885 |
| US-20170001995-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | FOXM1, SF3B1, SF3B5 | ALDH1A1 336/4885HPGD 2399/4885ALOX15 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.